TherapeuticsMD Competitors

Stocks . USA . 
Stock . TherapeuticsMD
TXMD Stock  USD 2.19  0.06  2.67%   
TherapeuticsMD competes with ProPhase Labs, Aytu BioScience, Biofrontera, Biomx, and Gelteq Limited; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing TherapeuticsMD competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of TherapeuticsMD to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out TherapeuticsMD Correlation with its peers.
For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.

TherapeuticsMD vs ProMIS Neurosciences Correlation

Weak diversification

The correlation between TherapeuticsMD and PMN is 0.39 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding TherapeuticsMD and PMN in the same portfolio, assuming nothing else is changed.

Moving together with TherapeuticsMD Stock

  0.67LPCN LipocinePairCorr

Moving against TherapeuticsMD Stock

  0.67BRK-A Berkshire HathawayPairCorr
  0.58HPQ HP IncPairCorr
  0.47MSFT MicrosoftPairCorr
  0.44MMM 3M CompanyPairCorr
  0.41VLCN Volcon Inc Symbol ChangePairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.102.009.47
Details
Intrinsic
Valuation
LowRealHigh
0.142.8610.33
Details
Naive
Forecast
LowNextHigh
0.041.929.38
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.281.942.60
Details

TherapeuticsMD Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between TherapeuticsMD and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of TherapeuticsMD and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of TherapeuticsMD does not affect the price movement of the other competitor.

High positive correlations

EKSO
+ 0.75
AYTU
ERNA
+ 0.74
PRPH
MPLT
+ 0.59
AYTU
PHGE
+ 0.56
BFRI
PMN
+ 0.5
PHGE
PHGE
+ 0.44
PRPH
  

High negative correlations

AYTU
- 0.76
PRPH
MPLT
- 0.55
PHGE
MPLT
- 0.54
PRPH
PHGE
- 0.52
AYTU
EKSO
- 0.36
PRPH
EKSO
- 0.34
GELS

Risk-Adjusted Indicators

There is a big difference between TherapeuticsMD Stock performing well and TherapeuticsMD Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze TherapeuticsMD's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
PRPH  8.01 (3.98) 0.00  1.92  0.00 
 0.00 
 11.11 
(22.22)
 77.27 
AYTU  2.68  0.22  0.05  0.47  3.70 
(2.68)
 4.69 
(5.94)
 16.84 
BFRI  3.74 (0.47) 0.00 (0.11) 0.00 
 0.00 
 6.76 
(7.59)
 34.13 
PHGE  9.19 (0.06) 0.00  0.05  12.17 
(9.77)
 14.44 
(18.87)
 88.38 
GELS  4.49 (0.25) 0.00 (0.12) 0.00 
 0.00 
 6.90 
(7.34)
 55.89 
EKSO  6.35  1.67  0.26  0.92  5.50 
(7.47)
 10.72 
(9.07)
 112.11 
ERNA  4.99 (1.79) 0.00  3.83  0.00 
 0.00 
 6.90 
(8.11)
 41.43 
MPLT  4.03  0.05  0.03  0.11  4.01 
(5.31)
 8.39 
(7.08)
 39.27 
AMS  1.29  0.03  0.00  0.14  1.24 
(2.06)
 3.81 
(2.33)
 10.96 
PMN  5.00  0.60  0.07 (1.67) 6.02 
(5.89)
 13.32 
(9.37)
 38.10 

TherapeuticsMD Competitive Analysis

The better you understand TherapeuticsMD competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, TherapeuticsMD's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across TherapeuticsMD's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TXMD PRPH AYTU BFRI PHGE GELS EKSO ERNA MPLT AMS
 2.67 
 2.19 
TherapeuticsMD
 12.50 
 0.14 
ProPhase
 3.91 
 2.39 
Aytu
 2.38 
 0.82 
Biofrontera
 13.80 
 4.56 
Biomx
 6.98 
 0.80 
Gelteq
 11.22 
 10.41 
Ekso
 44.12 
 0.38 
Eterna
 6.55 
 15.70 
MapLight
 2.27 
 2.15 
American
Market Volatility
(90 Days Market Risk)
Dangerous
Dangerous
Very risky
Dangerous
Somewhat reliable
Out of control
Risky
Out of control
Slightly risky
Unstable
Market Performance
(90 Days Performance)
Good
Weakest
Mild
Weakest
Weakest
Weakest
Fair
Weakest
Weak
Soft
Odds of Financial Distress
(Probability Of Bankruptcy)
Strong
Strong
High
Risky
Risky
Risky
Strong
Risky
Low
Small
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Hold
Current Ratio
0.57
4.2
1.02
3.16
7.44
N/A
8.16
3.08
N/A
3.64
Net Asset
38.82 M
63.2 M
124.18 M
22.1 M
43.23 M
21.48 M
26.65 M
5.27 M
N/A
60.2 M
Profit Margin
0.11
N/A
-0.39
-0.47
N/A
N/A
-0.71
N/A
N/A
-0.0765
EBITDA
(2.98 M)
(32.34 M)
(4.67 M)
(14.44 M)
(13.12 M)
(3.53 M)
(9.45 M)
(36.12 M)
N/A
8.91 M
Operating Margin
-0.38
-5.4
-0.13
-0.9
N/A
-29.69
-0.33
N/A
N/A
0.0067
Current Valuation
25.53 M
7.92 M
22.16 M
11.59 M
26.35 M
11.94 M
35.98 M
4.02 M
N/A
34.36 M
Price To Book
0.95
0.0932
1.15
0.65
26.81
0.83
3.49
1.83
N/A
0.58
Retained Earnings
(951.82 M)
(58.39 M)
(333.54 M)
(117.41 M)
(180.7 M)
(18.14 M)
(250.47 M)
(231.54 M)
N/A
5.82 M
Current Asset
70.68 M
9.73 M
6.36 M
N/A
N/A
N/A
17.57 M
N/A
N/A
6.01 M
Beta
0.52
-0.5
0.36
0.63
1.66
N/A
0.83
6.74
N/A
0.13
Number Of Employees
1
96
82
92
52
7
61
6
114
81
Shares Outstanding
11.57 M
4.74 M
10.73 M
11.65 M
1.53 M
10.71 M
3.56 M
7.85 M
N/A
6.57 M
Cash Flow From Operations
732 K
(17.54 M)
(1.94 M)
(10.27 M)
(36.98 M)
(5.52 M)
(9.85 M)
(15.84 M)
N/A
167 K
Total Debt
7.17 M
24.57 M
22.94 M
4.92 M
9.58 M
4.22 M
5.98 M
684 K
N/A
23.23 M
Return On Equity
0.0027
-2.2
-1.09
-11.92
-1.54
-0.43
-0.85
-22.64
N/A
-0.12
Return On Asset
-0.0273
-0.23
-0.0022
-0.65
-0.48
-0.15
-0.27
-0.89
N/A
0.0057
Number Of Shares Shorted
87.46 K
300.24 K
542.71 K
251.79 K
51.43 K
1 M
305.75 K
138.51 K
N/A
1.09 K
Book Value Per Share
2.37
1.65
1.32
-0.22
-5.76
1.1
3.69
0.46
N/A
3.77
Current Liabilities
10.67 M
6.25 M
8.73 M
N/A
N/A
N/A
5.51 M
N/A
N/A
8.7 M
Total Asset
38.82 M
63.2 M
124.18 M
22.1 M
43.23 M
21.48 M
26.65 M
5.27 M
N/A
60.2 M
Debt To Equity
0.67
0.19
0.47
N/A
0.59
N/A
0.068
0.19
N/A
0.62
Short Ratio
0.74
0.08
3.56
0.63
0.9
0.37
0.05
0.8
N/A
0.11
Target Price
5.0
13.8
9.33
6.0
165.0
N/A
9.5
3.0
N/A
4.5
Shares Owned By Institutions
28.73
3.87
34.03
25.49
34.6
0.86
4.76
6.9
N/A
12.65
Market Capitalization
25.35 M
711.02 K
25.22 M
9.76 M
6.96 M
8.57 M
33.35 M
5.34 M
N/A
14.45 M
Price To Earning
-10.22
6.59
-0.77
N/A
N/A
N/A
-0.67
N/A
N/A
18.67
Price To Earnings To Growth
-0.73
N/A
N/A
N/A
N/A
N/A
N/A
-0.03
N/A
N/A
Price To Sales
9.07
0.14
0.4
0.26
N/A
20.74
2.26
5340.41
N/A
0.49
Net Income
(2.31 M)
(49.52 M)
(13.56 M)
(17.76 M)
(17.73 M)
(6.65 M)
(11.33 M)
(44.54 M)
N/A
1.53 M
Earnings Per Share
0.01
-19.8
-2.0
-1.5
-31.94
-0.47
-5.38
45.81
N/A
-0.35
Shares Owned By Insiders
1.54
5.05
5.13
12.18
17.22
47.52
25.81
66.64
N/A
44.9
Revenue
1.76 M
6.77 M
66.38 M
37.3 M
N/A
165.65 K
17.93 M
582 K
N/A
28.34 M
Working Capital
7.09 M
(1.5 M)
16.11 M
8.68 M
12.25 M
(4.13 M)
11.31 M
(586 K)
N/A
15.85 M
Cash And Equivalents
27.08 M
27.5 M
23.81 M
31.91 M
45.74 M
N/A
31.91 M
19.41 M
N/A
11.03 M
Cash Per Share
2.86
1.72
0.38
1.36
1.53
N/A
2.45
6.6
N/A
1.94
Gross Profit
2.8 M
987 K
41.87 M
23.94 M
N/A
297.74 K
7.89 M
1 K
N/A
13.4 M
Day Typical Price
2.22
0.14
2.39
0.84
4.73
0.82
10.23
0.37
16.23
2.17
Accumulation Distribution
0.1
0.13
3773.97
16169.2
0.11
0.0814
33328.42
1 M
0.12
333.64
Market Facilitation Index
0.24
0.02
0.0
N/A
0.54
0.07
0.0
N/A
2.02
0.0
Daily Balance Of Power
(0.25)
(1.00)
0.4091
(0.29)
(1.35)
(0.86)
0.84
(2.73)
(0.54)
(0.71)
Period Momentum Indicator
(0.06)
(0.02)
0.09
(0.02)
(0.73)
(0.06)
1.05
(0.30)
(1.10)
(0.05)
Rate Of Daily Change
0.97
0.88
1.04
0.98
0.86
0.93
1.11
0.56
0.93
0.98
Day Median Price
2.24
0.14
2.39
0.85
4.81
0.83
10.14
0.37
16.5
2.19
Price Action Indicator
(0.08)
(0.01)
0.045
(0.04)
(0.62)
(0.06)
0.8
(0.13)
(1.35)
(0.06)
Coefficient Of Variation
651.36
(286.03)
1232.8
(2,436)
14081.25
(5,260)
729.56
(450.59)
3051.55
2153.49
Mean Deviation
5.22
8.01
2.68
3.74
9.19
4.49
6.35
4.99
4.03
1.29
Jensen Alpha
0.9661
(3.98)
0.2236
(0.47)
(0.06)
(0.25)
1.67
(1.79)
0.0484
0.0332
Total Risk Alpha
0.3955
(5.32)
(0.07)
(0.89)
(1.29)
(0.88)
0.503
(2.64)
(0.41)
(0.11)
Sortino Ratio
0.1466
N/A
0.0476
N/A
8.0E-4
N/A
0.2617
N/A
0.0251
(0)
Downside Variance
51.22
N/A
15.8
N/A
158.44
N/A
44.79
N/A
18.21
2.59
Standard Deviation
7.42
11.84
3.44
6.27
13.97
7.42
13.43
8.19
6.01
1.88
Kurtosis
2.02
6.13
0.3137
8.26
9.72
14.0
37.47
11.36
10.83
3.91
Potential Upside
13.33
11.11
4.69
6.76
14.44
6.9
10.72
6.9
8.39
3.81
Treynor Ratio
0.5519
1.92
0.4727
(0.11)
0.0466
(0.12)
0.9161
3.83
0.1075
0.1399
Maximum Drawdown
43.93
77.27
16.84
34.13
88.38
55.89
112.11
41.43
39.27
10.96
Variance
55.05
140.15
11.82
39.37
195.19
55.08
180.36
67.04
36.12
3.52
Market Risk Adjusted Performance
0.5619
1.93
0.4827
(0.1)
0.0566
(0.11)
0.9261
3.84
0.1175
0.1499
Risk Adjusted Performance
0.1326
(0.27)
0.073
(0.02)
0.0151
(0.01)
0.1198
(0.17)
0.0351
0.0431
Skewness
0.1403
1.31
(0.57)
1.43
1.6
2.78
5.42
(2.36)
2.36
1.44
Semi Deviation
6.42
N/A
3.7
N/A
12.17
N/A
5.5
N/A
4.01
1.24
Information Ratio
0.1414
(0.36)
0.055
(0.06)
7.0E-4
(0.03)
0.1304
(0.23)
0.0179
(0)
Value At Risk
(10.59)
(22.22)
(5.94)
(7.59)
(18.87)
(7.34)
(9.07)
(8.11)
(7.08)
(2.33)
Expected Short fall
(5.96)
N/A
(2.68)
N/A
(9.77)
N/A
(7.47)
N/A
(5.31)
(2.06)
Downside Deviation
7.16
N/A
3.97
N/A
12.59
N/A
6.69
N/A
4.27
1.61
Semi Variance
41.28
N/A
13.68
N/A
148.11
N/A
30.29
N/A
16.04
1.53

TherapeuticsMD Competition Performance Charts

Five steps to successful analysis of TherapeuticsMD Competition

TherapeuticsMD's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by TherapeuticsMD in relation to its competition. TherapeuticsMD's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of TherapeuticsMD in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact TherapeuticsMD's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to TherapeuticsMD, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your TherapeuticsMD position

In addition to having TherapeuticsMD in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run USD Crypto Fund Thematic Idea Now

USD Crypto Fund
USD Crypto Fund Theme
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
View All  Next Launch
When determining whether TherapeuticsMD is a strong investment it is important to analyze TherapeuticsMD's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact TherapeuticsMD's future performance. For an informed investment choice regarding TherapeuticsMD Stock, refer to the following important reports:
How To Invest In TherapeuticsMD
Details
Is TherapeuticsMD Stock a good investment?
Details
What is TherapeuticsMD's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out TherapeuticsMD Correlation with its peers.
For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Will Pharmaceuticals sector continue expanding? Could TherapeuticsMD diversify its offerings? Factors like these will boost the valuation of TherapeuticsMD. If investors know TherapeuticsMD will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every TherapeuticsMD data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
TherapeuticsMD's market price often diverges from its book value, the accounting figure shown on TherapeuticsMD's balance sheet. Smart investors calculate TherapeuticsMD's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since TherapeuticsMD's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between TherapeuticsMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if TherapeuticsMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TherapeuticsMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY